A Professional Service Provider for the Pharma Industry
In 2024, the ECDC published a detailed review of flu vaccine studies [1]. In particular, the report examined published trials of newer flu vaccines. As is well known, the older vaccines provide significant protection, but efficacy is diminished in certain populations. Especially the elderly are at an increased risk of Continue reading INFLUENZA VACCINATION IN THE ELDERLY
There are studies that are bound to succeed, and those that are likely to fail. A failed trial is nothing to be proud of – and in this case, it was a gamble against overwhelming odds. We feel the Gilead marketing department was pushing their luck big time with this Continue reading Obeldesivir Fails in Yet Another Study
Two posters on tacicepts caught our eyes. First is the Tumlin publication on povetacicept, an oral presentation in the “Late-Breaking Research” session. This is an interim look at Phase 1b study data reporting on 17 IgAN patients treated for 48 weeks with a dose of 80 mg and 30 patients Continue reading TACICEPTS VYING FOR YOUR ATTENTION